These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17671082)

  • 1. Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice.
    Emmenegger U; Shaked Y; Man S; Bocci G; Spasojevic I; Francia G; Kouri A; Coke R; Cruz-Munoz W; Ludeman SM; Colvin OM; Kerbel RS
    Mol Cancer Ther; 2007 Aug; 6(8):2280-9. PubMed ID: 17671082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.
    Jounaidi Y; Waxman DJ
    Cancer Res; 2001 Jun; 61(11):4437-44. PubMed ID: 11389073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.
    Wu J; Waxman DJ
    Cancer Lett; 2014 Oct; 353(2):272-80. PubMed ID: 25069038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model.
    Huang Z; Raychowdhury MK; Waxman DJ
    Cancer Gene Ther; 2000 Jul; 7(7):1034-42. PubMed ID: 10917206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy.
    Schwartz PS; Chen CS; Waxman DJ
    Cancer Gene Ther; 2003 Aug; 10(8):571-82. PubMed ID: 12872138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy.
    Shaked Y; Emmenegger U; Francia G; Chen L; Lee CR; Man S; Paraghamian A; Ben-David Y; Kerbel RS
    Cancer Res; 2005 Aug; 65(16):7045-51. PubMed ID: 16103050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model.
    Chen CS; Jounaidi Y; Su T; Waxman DJ
    Cancer Gene Ther; 2007 Dec; 14(12):935-44. PubMed ID: 17853921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors.
    Huang Z; Waxman DJ
    Cancer Gene Ther; 2001 Jun; 8(6):450-8. PubMed ID: 11498765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens.
    Emmenegger U; Man S; Shaked Y; Francia G; Wong JW; Hicklin DJ; Kerbel RS
    Cancer Res; 2004 Jun; 64(11):3994-4000. PubMed ID: 15173013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.
    Emmenegger U; Morton GC; Francia G; Shaked Y; Franco M; Weinerman A; Man S; Kerbel RS
    Cancer Res; 2006 Feb; 66(3):1664-74. PubMed ID: 16452226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide administered repeatedly to the male rat and as a single dose to the female rat. Its effects on hepatic and pulmonary P450 and associated enzymes.
    Angley MT; Sansom LN; Stupans I
    Xenobiotica; 1995 Nov; 25(10):1051-62. PubMed ID: 8578761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide.
    Emmenegger U; Francia G; Chow A; Shaked Y; Kouri A; Man S; Kerbel RS
    Neoplasia; 2011 Jan; 13(1):40-8. PubMed ID: 21245939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse.
    Pass GJ; Carrie D; Boylan M; Lorimore S; Wright E; Houston B; Henderson CJ; Wolf CR
    Cancer Res; 2005 May; 65(10):4211-7. PubMed ID: 15899812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
    Chen L; Waxman DJ; Chen D; Kufe DW
    Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity.
    Yu LJ; Drewes P; Gustafsson K; Brain EG; Hecht JE; Waxman DJ
    J Pharmacol Exp Ther; 1999 Mar; 288(3):928-37. PubMed ID: 10027828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression.
    Chen CS; Doloff JC; Waxman DJ
    Neoplasia; 2014 Jan; 16(1):84-96. PubMed ID: 24563621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose metronomic delivery of cyclophosphamide is less detrimental to granulosa cell viability, ovarian function, and fertility than maximum tolerated dose delivery in the mouse.
    Dynes J; Osz K; Hooper A; Petrik J
    Biol Reprod; 2017 Sep; 97(3):449-465. PubMed ID: 29024988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector.
    Ichikawa T; Petros WP; Ludeman SM; Fangmeier J; Hochberg FH; Colvin OM; Chiocca EA
    Cancer Res; 2001 Feb; 61(3):864-8. PubMed ID: 11221871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mouse model with liver-specific deletion and global suppression of the NADPH-cytochrome P450 reductase gene: characterization and utility for in vivo studies of cyclophosphamide disposition.
    Gu J; Chen CS; Wei Y; Fang C; Xie F; Kannan K; Yang W; Waxman DJ; Ding X
    J Pharmacol Exp Ther; 2007 Apr; 321(1):9-17. PubMed ID: 17218484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
    Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
    Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.